share_log

Novo-Nordisk A/S | 6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons

SEC announcement ·  Feb 14 08:06
Summary by Moomoo AI
On February 14, 2024, Novo Nordisk A/S, a leading global healthcare company, reported transactions of its shares by board members, executives, and their associated persons. The disclosure, in compliance with Article 19 of Regulation No. 596/2014 on market abuse, detailed a sale of shares by Elisabeth Dahl Christensen, a member of the Board of Directors. The transaction involved the sale of 100 shares at a price of DKK 835.70 per share, conducted on February 13, 2024, at Nasdaq Copenhagen. Novo Nordisk, with a heritage in diabetes, is committed to defeating serious chronic diseases and employs approximately 63,400 people worldwide. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.
On February 14, 2024, Novo Nordisk A/S, a leading global healthcare company, reported transactions of its shares by board members, executives, and their associated persons. The disclosure, in compliance with Article 19 of Regulation No. 596/2014 on market abuse, detailed a sale of shares by Elisabeth Dahl Christensen, a member of the Board of Directors. The transaction involved the sale of 100 shares at a price of DKK 835.70 per share, conducted on February 13, 2024, at Nasdaq Copenhagen. Novo Nordisk, with a heritage in diabetes, is committed to defeating serious chronic diseases and employs approximately 63,400 people worldwide. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more